KEY TAKEAWAYS
- The study aimed to investigate the role of CDK6 as a prognostic marker for immunotherapy response and survival outcomes in patients with bladder cancer.
- Researchers showed CDK6 expression may predict prognosis and immunotherapy response, highlighting its potential as a therapeutic target.
Bladder cancer is a significant health concern globally. Understanding the molecular mechanisms driving its progression, especially concerning immunotherapy response and survival, is crucial.
Xiaojie Zhao and the team aimed to investigate the biological role of Cyclin-dependent kinase 6 (CDK6) in bladder cancer, focusing on its expression characteristics, prognostic value, and potential as a therapeutic target.
Researchers utilized raw data from publicly available databases and a single-centre retrospective case series. Bioinformatics analysis and immunohistochemistry were employed to assess CDK6 expression in bladder cancer. They investigated the relationship between CDK6 expression and clinicopathological characteristics, including immunotherapy response and patient survival.
The findings revealed a significant association between high CDK6 expression and poor prognosis in patients with bladder cancer. High CDK6 expression was also linked to a diminished response to immunotherapy. Furthermore, the study suggested that CDK6 influences tumor behaviour by regulating immune status, metabolism, and cell cycle pathways.
The CDK6 demonstrated potential as an independent biomarker for predicting both the prognosis and the efficacy of immunotherapy in bladder cancer. A deeper understanding of its mechanisms could lead to novel treatment strategies.
This study was supported by Shanghai Pujiang Program (22PJ1412000) and the National Natural Science Foundation of China (No. 81972408).
Source: https://pubmed.ncbi.nlm.nih.gov/39310261/
Zhao X, Yu X, Li W, et al. (2024). “CDK6 as a Biomarker for Immunotherapy, Drug Sensitivity, and Prognosis in Bladder Cancer: Bioinformatics and Immunohistochemical Analysis.” Int J Med Sci. 2024;21(12):2414-2429. Published 2024 Sep 16. doi:10.7150/ijms.101043
